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ABSTRACT
Diadenosine polyphosphates are a group of nucleotides which modulate
physiological processes in the eye such as tear secretion, corneal wound healing
and intraocular pressure. This regulation is carried out by P2 purinergic receptors
termed P2X and P2Y as well as dinucleotide receptors. Diadenosine polyphosphates
are present in tears and when topically applied they can produce tear secretion in
a process mediated by P2Y receptors. P2Y receptors are also present in corneal
epithelial cells and they can accelerate the rate of re-epithelialization after
superficial injuries. On the other hand, intraocular pressure is reduced by all those
nucleotides activating P2X receptors. Due to the importance of the presence of
these receptors in ocular structures it is possible to think in the use of dinucleotides,
naturally occurring and synthetic ones, for the treatment of dry eye, corneal injuries
and glaucoma.
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RESUMEN
Nuevas perspectivas en farmacología ocular:
los nucleótidos como agentes terapéuticos
Los diadenosina polifosfatos son un grupo de nucleótidos que modulan proce-
sos relevantes de la fisiología ocular como la secreción corneal, la cicatrización
corneal y la presión intraocular. Esta regulación es llevada a cabo a través de re-
ceptores purinérgicos del tipo P2 como son los P2X y P2Y, así como por el recep-
tor de dinucleótidos. Los diadenosina polifosfatos están presentes en las lágrimas
y cuando son instilados tópicamente pueden inducir la secreción lagrimal en un
proceso mediado por receptores del tipo P2Y. También los receptores P2Y están
presentes en las células del epitelio corneal que aceleran el proceso de cicatrización
corneal tras una lesión superficial. Por otra parte, la presión intraocular se puede
reducir aplicando aquellos nucleótidos que activen receptores del tipo P2X. Debido
a la presencia de estos receptores en las estructuras oculares es posible pensar en
el uso de los dinucleótidos, naturales o sintéticos, para el tratamiento del ojo seco,
heridas corneales y el glaucoma.
Palabras clave: Cicatrización corneal.—Diadenosina polifosfato.—Ojo seco.—
Glaucoma.—Presión intraocular.—Receptores de nucleótidos.
OCULAR PATHOLOGIES
In spite of the number of ocular pathologies is immense, three
pathological states are now important due to their incidence in
modern society: dry eye, corneal wound healing and glaucoma. Apart
from the incidence of all of them in the world population, the two
first do not have an effective treatment in most of the cases. On the
other hand glaucoma has several pharmacological treatments but
most of them present wide side effects. In the three cases the
development of new pharmacological compounds is necessary.
The strategy of pharmaceutical companies regarding the
discovery of new compounds is mainly the variation of well-
established pharmaceutical species by modifying their chemical
structures in order to obtain better agonists, antagonists or enzyme
inhibitors. Also companies, by means of their research and
development departments try to find new molecules, receptors and
enzymes as pharmacological targets. Nonetheless, the discovery of
new attractive compounds is mostly carried out by research centres
and universities. Taking into account this point of view, we have
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modestly contributed to the discovery of new biological molecules
and their implications in the eye physiology and physiopathology.
We have investigated the role of extracellular nucleotides and
dinucleotides in the eye. Nucleotides and dinucleotides can exert
extracellular actions by means of the activation of different
membrane receptors termed P2 purinergic receptors, which are
described in the following section.
RECEPTORS FOR EXTRACELLULAR NUCLEOTIDES
The effects of nucleotides are due to the existence of receptors
in cell membranes termed P2 receptors that transmit the message
into the cell producing certain changes in the cell biochemistry. In
this sense, nucleotides can bind and activate to two major types
of receptors, metabotropic nucleotide receptors or P2Y receptors
and ionotropic P2X receptors (1, 2). P2Y receptors are seven
transmembrane domain proteins coupled to phospholipase C via G
proteins, although some of the newly cloned P2Y receptors can
regulate adenylate cyclase and presumably can be coupled to other
second messenger system (3-5). The family of P2Y receptor is formed
by six cloned receptors termed as P2Y1, P2Y2, P2Y3, P2Y4, P2Y6 and
P2Y11, P2Y12, P2Y13, and the UDP-glucose receptor (3, 6-9). P2X
receptors are receptor-operated ion channels selective to small
cations such as Na+ and Ca2+. These receptors are involved in fast
synaptic transmission between neurones and between autonomic
nerves and smooth muscle, where ATP is the main transmitter.
Molecular biology has permitted the identification of up to seven
P2X receptors named P2X1– P2X7. It is generally accepted by the
scientific community that these receptors are formed by more than
one subunit because each subunit contains only two transmembrane
domains. The differences established between the pharmacological
experiments performed in expression systems and in native tissues
strongly suggests that P2X receptors are heteromeric rather than
homomeric receptors (for a full review, see 10).
The eye contains P2 receptors in its structures and thus it is
susceptible to be activated by the presence of nucleotides. These
changes in eye physiology can include lachrymal apparatus, cornea,
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ciliary body, iris, trabecular meshwork, lens, and the retina (11, 12).
Not all the structures previously mentioned have been fully
investigated; nevertheless it has been possible to understand the role
of nucleotides and dinucleotides on corneal surface and intraocular
pressure (IOP).
THE OCULAR SURFACE
There are two main pathological states regarding the ocular
surface. On the one hand dry eye, and on the other hand corneal
wound healing that occurs after superficial injuries. None of them
have efficacious treatments and are lacking of the discovery of new
substances for their care.
Dry eye and tear secretion
Tear secretion is an important physiological process because tear
forms the interface between the air and the ocular tissues. Tears
protect the corneal surface with antibacterial systems, such as
lysozyme and lactoferrin, provide the epithelium with nutrients, and
lubricate the eyelids. Also, they wash away those particles that may
damage the cornea. There are situations in which some problems
in the volume or in the quality of tears occur, and therefore may
produce several negative effects such as corneal function failures,
discomfort, and even pain (a sandy feeling that may be accompanied
by irritation). If the problem is related to a reduction in the total
volume, the mucin layer of the corneal epithelium will not guarantee
a uniform film, thus shortening the tear break-up time. Specialists
such as optometrists and ophthalmologists, by means of dyes such
as fluorescein, Bengal pink, or lissamine green, can follow these
changes of the normal tear film to a pathological state. Tear film
stability is particularly important for contact lens wearing, because
a deficient volume or a poor quality will make the adaptation of
contact lenses difficult. Between 20% and 30% of contact lens
wearers develop ocular dryness. Extreme conditions such as air
conditioning, wind, heaters, or a prolonged read without a regular
blinking frequency will facilitate an increase of tear evaporation.
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Within the above percentage, between 12% and 20% reduce
significantly the use of contact lenses because of the mentioned
discomfort. Most of the approaches to solve this problem lie in
changing the tear viscosity by the application of compounds
based on preparations containing carboxymethylcellulose,
hydroxypropylcellulose, or polyvinylalcohol. There are no good
pharmacological solutions available to restore normal tear film
properties.
Nucleotides are interesting compounds restoring the normality
in those individuals presenting ocular dryness. Nucleotides and
dinucleotides have been described in human and experimental
animal tears. The most representative ones are the diadenosine
polyphosphates, which are dinucleotides formed by two adenosines
linked by a variable number of phosphates which can fluctuate
between 2 and 7 (abbreviated as ApnA, n = 2-7) (13). These
dinucleotides have been described by means of high performance
liquid chromatography (HPLC) as presented in Figure 1A.
Diadenosine triphosphate, Ap3A, diadenosine tetraphosphate Ap4A
and diadenosine pentaphoshate Ap5A have been described in human
tears while Ap3A was absent in rabbit tears. The concentration
between human and rabbit tears were also different. While in
humans the concentrations of the dinucleotides are in the nanomolar
range in the animal it was in the micromolar one (14, 15).
One interesting point after demonstrating their presence in tears
is to understand where these dinucleotides come from. Experiments
performed in healthy human volunteers demonstrate that nucleotides
and dinucleotides are released from the ocular surface, probably
both cornea and conjunctiva by mechanical stress (16). It has been
demonstrated that an increase in the blinking frequency produces
an associated increase in the diadenosine polyphosphate tear
concentration. Although the molecular mechanism has not been
elucidated, it is possible, as occurs in the central nervous system,
that nucleotides are liberated from nerve terminals, but there is
evidence that nucleotides can be transported out of cells. Epithelial
cells (17, 18), and in particular ocular epithelial cells, use different
transport mechanisms as a regulated procedure for nucleotide
release. The ATP binding cassette (ABC) transporter, the cystic
fibrosis transmembrane conductance regulator (CFTR) or
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glycoprotein P have been proposed as elements involved in the
release of nucleotides (19, 20). It has been described that ATP leaves
corneal endothelial cells by means of connexin hemichannels when
these cells are stimulated mechanically (21). We think that the latter
may be the most plausible mechanism although we cannot discard
the other previously suggested.
Since diadenosine polyphosphates are present naturally in tears,
experiments were performed in order to investigate whether the
topical application of these substances were able to change tear
production. Of all the tested dinucleotides (Ap2A-Ap6A, at 100 μM),
Ap4A, Ap5A and Ap6A were able to increase tear secretion between
20% to 60%, the best being Ap4A (Figure 1B). Some mononucleotides
also were able to increase tear production UTP and ATP being the
best ones and increasing tearing 60% and 40% respectively over the
control values (14).
FIGURE 1. Presence and effect of diadenosine polyphosphates on tear
secretion. A. The presence of diadenosine polyphosphates has been identified by
high performance liquid chromatography indicating the presence of diadenosine
triphosphate, Ap3A, diadenosine tetraphosphate, Ap4A and diadenosine
pentaphosphate, Ap5A in human tears. B. The topical application of 100 μM
of the dinucleotides produce a different behaviour on the rate of tear secretion
depending on the phosphate chain. Among all, Ap4A was able to increase tear
secretion 60% above the normal tear production.
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When a wide range of concentrations of the dinucleotides were
used, it was possible to establish concentration-response curves
which permitted to calculate EC50 values for the diadenosine
polyphosphates. Ap4A presented an EC50 value of 2.76 μM, Ap5A a
value of 1.77 μM and Ap6A a value of 3.16 μM (14).
The ability of some diadenosine polyphosphates activating tear
production, is indicating that they can be considered as constitutive
activators of tear release being this mechanism independent from
the one that naturally control the main lachrymal glands (16).
Moreover, the topical application of some of these compounds such
as Ap4A, may be useful for the treatment of dry eye specially those
cases in which this pathology takes place with a lack of tear volume.
The design of new pharmacological compounds with nucleotidic
structure such as diquafosol aka INS365, brings interesting
expectations for dry eye treatment. This compound is a congener
of Ap4A (diuridine tetraphosphate, Up4U) and presents a similar
behaviour to the one observed for UTP or diadenosine
polyphosphates (22). This substance enhanced tear secretion even
after consecutive doses for several days as revealed by Schirmer
scores. Tear secretion was increased 5-15 min after the compound
application, and the effect persisted longer with solution of
diquafosol of 8.5%. The clinical trials performed with humans with
dry eye disease demonstrated good toleration in all the individuals
at all the doses assayed. Applications of 25 μL of 0.5%, 1%, 2%, and
5% w/v produced increased tear secretion in patients with mild to
moderate dry eye. All these results suggest the unequivocal utility of
this compound as a therapeutic agent for dry eye syndrome (23).
In a model of dry eye developed in rats, the topical application of
the dinucleotide Up4U (diquafosol) increased tear secretion, surface
health, and release of glycoproteins from goblet cells. These
interesting properties of this dinucleotide indicate the therapeutic
benefits of this compound for the treatment of dry eye (24).
Wound healing
The cornea is the most superficial part of the eye. This structure
is suitable of having different damages coming from the
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environmental medium. Foreign bodies, dirty or defective contact
lenses and also refractive surgery, produce injury on the corneal
epithelium, the most external part of the cornea.
The corneal wound healing process occurs in three main steps:
a lag phase in which after the injury happens cells surrounding
the affected area detach from Bowman’s membrane and those
cells which are affected by the injury are eliminated by
polymorphonuclear leukocytes. A second step in which the cells in
the periphery of the affected area move centripetally to cover the
free space, and finally, a proliferative step in which cells divide to
give the corneal epithelium its normal thickness.
Although all these stages are relevant, a critical step is the
migration phase since it avoids the invasion of bacteria to inner
parts of the eye, and other problems derived from an inadequate
corneal thickness.
In vivo experiments
We have investigated the possible effect of mono and
dinucleotides on the corneal wound healing process. The presence
of these substances in tears may suggest a role of them in the
healing process, therefore it was evaluated the possible role of
these compounds on corneal wound healing in vivo by means
of New Zealand white rabbits which were injured with n-heptanol.
In the absence of any added nucleotide (vehicle) the time of
re-epithelialisation of a 3 mm corneal wound is of 32.2 hours and
the rate of migration is 72.4 μm/hour. When the wounds are treated
with 100 μM UTP or Ap4A the rate of healing was accelerated to
121.6 μm/h and 93.7 μm/h respectively. None of the other mono or
dinucleotides did significantly modify the rate of healing (25).
The positive effect of these two compounds is mediated by P2Y
receptors and presumably P2Y2 since UTP and Ap4A are full agonists.
Also, the application of antagonists such as suramin, PPADS or
reactive blue 2, were able to reverse the effect produced by UTP and
Ap4A. Unfortunately due to the lack of more selective antagonists it
was not possible to fully confirm the P2Y receptor subtype (25).
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In vitro experiments
In order to understand the molecular mechanism that make
corneal epithelial cells to migrate faster after the challenge with
some nucleotides and dinucleotides, experiments were performed
with corneal epithelial cells in primary cultures (Figure 2A).
FIGURE 2. Effect of dinucleotides on corneal wound healing. A. Corneal
epithelial cells were isolated and seeded as primary cultures which can be observed
under Normaski optics and provide positive labelling to the P2Y2 receptor
antibody. B. Diadenosine polyphosphates were able modify the rate of
re-epithlialization, Ap4A being the best dinucleotide in its ability to accelerate
cell migration.
The treatment of epithelial cells with diadenosine polyphosphates
after scratching the monolayer with a pipette tip, demonstrated that
as occur in vivo, Ap4A was able to accelerate the rate of healing while
Ap3A and Ap5A clearly delayed the rate of healing (Figure 2B). Other
nucleotides, such as ADP did not modify the rate of healing when
compared to control. In both cases, a positive or negative effect on
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re-epithelialisation, the effects may be justified by the activation of
different P2Y receptors subtypes, according to our pharmacological
studies. It is clear that the pharmacology of P2 receptors is rather
complicated due to the lack of selective antagonists. A possible
picture of the receptors involved in the acceleration of re-
epithelialisation or its delay is maybe possible by studying the
behaviour of several purinergic agonists (26).
The increase in the rate of re-epithelialization has been observed
when Ap4A, and UTP were applied. This profile matches quite well
with that described by Lazarowski et al. (27), in which Ap4A and
UTP are the best agonists on the cloned P2Y2 receptor. A similar
P2Y2 profile has been previously described for corneal wound healing
in the in vivo experiments described in the previous paragraph. With
corneal epithelial cells in culture, it has been possible to detect some
dinucleotides which clearly reduce the rate of healing. Together with
the study of mononucleotides it was possible to obtain a profile for
those nucleotides reducing the rate of re-epithelialisation. A profile
with the ranking order Ap5A > Ap3A ≅ UDP suggests the involvement
of a P2Y6 receptor. This fact is altering the idea of the P2Y6 receptor
being a pyrimidinoceptor, sensitive to UTP and UDP. Nevertheless,
studies performed with diadenosine polyphosphates and P2Y6
receptors heterologously expressed in 1321N1 cells, demonstrate that
both Ap3A and Ap5A are agonists of the P2Y6 receptor although the
concentration required for the receptor stimulation are higher than
those of the best agonist, UDP (28). Also recently, the design of novel
dinucleoside polyphosphates with uridine as nucleoside moiety
(UpnU), demonstrate that some of them are quite effective activating
the P2Y6 receptor (29).
The involvement of metabotropic P2 receptors in corneal wound
healing has been reported by other groups (30-32). The presence of
P2Y2, P2Y4 and P2Y11, on corneal epithelial cells seem to be clear
from a pharmacological point of view. Discussion arises when the
presence of P2Y1 or P2Y6 is investigated. The assay of UDP together
with the enzyme hexokinase suggests the presence of a P2Y6 receptor
in these cells (30).
Concerning the second messenger system underlying the
activation of those receptors, it seems that both intracellular Ca2+
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mobilization (31, 32) the typical P2Y receptor second messenger
system, and MAPKinase cascade activation33 are involved. These
intracellular mechanisms which accelerate the rate of healing, seems
to be triggered by P2Y2 and P2Y4 membrane receptors (32). These
results match well with the effect of Ap4A, UTP and ATP we have
observed in our investigation, which indicates the activation of a
P2Y2 receptor.
Ap4A is effective inducing an increase in the rate of migration by
stimulating a P2Y2 receptor, while Ap3A and Ap5A do the opposite
by activating a P2Y6 receptor. This dual role of diadenosine
polyphosphates may have a physiological meaning in the intact
tissue. Corneal wound healing is a process that occurs in 3 main
steps as previously commented: lag phase, migration and mitosis
(33). It could be the case that in the intact corneal epithelium, P2Y2
receptors would be the relevant ones facilitating the migration rate
in intact corneas. It is necessary to take into consideration that in
primary corneal epithelial cells in culture, the lag phase is reduced.
This reduction is because the cells do not need to carry out some
pathophysiological processes that occur in the intact cornea after
injury. In the whole cornea, polymorphonuclear leukocytes remove
necrotic cells from the wound margin. Also, hemidesmosomal
attachments between the basament membrane and the basal cells
disappear (33). All these phenomena does not occur in our
preparation since it only contains a monolayer of epithelial cells.
On the other hand, P2Y6 would be critical stopping migration and
starting the third phase (mitosis). It is clear that we do not have any
evidence for the role of P2Y6 receptor to confirm this idea, but it
would not be strange to think about P2Y2 and P2Y6 as switchers that
control the transition from wound healing phase 2 to phase 3.
Nucleotides dinucleotides in the aqueous humour
and the control of intraocular pressure
Aqueous humour is a physiologically relevant fluid that permits
the nutrient supply to nonvascular structures such as the corneal
endothelial cells and the lens. This fluid contains measurable
amounts of both mono- and dinucleotides. The most relevant adenine
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mononucleotides found in the whole aqueous humour were AMP,
ADP, and ATP, which presented concentration values of 10.4 μM,
1.9 μM, and 1.0 μM, respectively (34). Investigations developed by
Mitchell et al. (18) describe the concentration of ATP in the ciliary
epithelium in particular in the immediate area where it is released.
The concentration values for ATP were between 4 and 8 μM. The
difference between both values may be as a consequence of either a
dilution effect or due to the activity of ecto-nucleotidases (35).
Diadenosine polyphosphates were also present in the aqueous
humour of the rabbit, at lower concentrations than ATP, their values
being 0.34 μM and 0.08 μM for Ap4A and Ap5A, respectively (34).
The presence of both mono and dinucleotides in the aqueous
humour is suggesting a physiological role of these substances in the
control of relevant processes such as intraocular pressure.
The control of intraocular pressure (IOP) is an important process
where nucleotides may participate as therapeutic agents. Glaucoma
is a pathology that, in many cases, is produced by an increase in the
IOP. Pathophysiology of elevated IOP is linked either with the
increased production of aqueous humour by ciliary body or an
increased outflow resistance. This raise in IOP is transmitted to the
retina, producing an occlusion of the posterior ciliary artery,
generating ischaemic optic atrophy and gradual retinal degeneration.
Moreover, the pressure can collapse optic nerve head structural
support and axons can be damaged by mechanical compression. The
final result of these complex negative actions is blindness (36).
IOP is a physiological process highly controlled by the nervous
system. The sympathetic and parasympathetic nervous systems
regulate both the production and drainage of aqueous humour. Part
of the pharmacological treatments for ocular hypertension lie in the
interference of either the synthesis of the aqueous humour
(controlled by the sympathetic system) or of its removal (regulated
by the parasympathetic). In this sense, many pharmacological
approaches have tried to reduce IOP by altering the functioning of
the innervation that controls the dynamics of aqueous humour. The
use of beta-blockers in order to reduce the production of aqueous
humour such as betaxolol or timolol is currently practised. Also, the
application of cholinergic agonists such as carbamylcholine has been
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used in order to reduce the resistance to aqueous outflow (37-39).
Compounds that do not interfere with the nervous system have been
used to reduce IOP. These include carbonic anhydrase inhibitors
(decreasing aqueous production) or more recently the use of
prostaglandin analogues such as latanoprost (Xalatan).
Until the year 2000, the only purines tested for their ability to
modify IOP were adenosine and derivatives that demonstrated
relevant physiological effects on IOP (40). Adenosine acting through
adenosine A2 receptors produces an increase in IOP when topically
applied to rabbit eyes, while A1 produce a decrease in IOP (41, 42).
The application of mono- and dinucleotides depicted a clear
pattern of modulators on IOP. Thus, mononucleotides were classified
under two main groups: on the one hand those elevating IOP and on
the other those reducing it. Among the first, 2-MeSATP, ATP-γ-S and
the natural compound ATP presented a clear increase on IOP, which
was maximal 2-3 h after the compound instillation. This profile fits
well with P2Y receptor pharmacology, although the destruction
of these nucleotides by means of ectonucleotidases and the
corresponding adenosine formation cannot be discarded (43). In this
sense, a recent work by Farahbakhsh and Cilluffo (35) described the
presence of P2Y1 and P2Y2 receptors in the rabbit ciliary body
epithelial cells, which may be responsible for the action of 2-
MeSATP, ATP-γ-S, as well as other P2Y agonists. On the contrary,
βγ-meATP and αβ-meATP produced a clear and marked reduction
in rabbit IOP. The time course to obtain the maximal effect was
similar to the one obtained for the hypertensive compounds (3 h).
Concentration-response analysis presented IC50 values of 1.52 mg/
mL and 0.55 mg/mL and a maximal reduction in IOP of 35.66% and
45.04% for αβ-meATP and βγ-meATP respectively. The hypotensive
effect produced by these two mononucleotides were blocked by
the P2 antagonist PPADS but were unaffected by the adenosine
antagonists DPCPX (43). βγ-meATP and αβ-meATP, activate P2
receptors, presumably P2X2 receptors, present in cholinergic
terminals that are in the trabecular meshwork. The activation of this
P2X2 receptor would generate an increase in acetylcholine release,
which facilitates both the relaxation of trabecular meshwork cells
and the elimination of aqueous humour (Figure 3).
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Diadenosine polyphosphates (ApnA) present a similar behaviour
as that observed for mononucleotides. Of all the tested dinucleotides,
Ap3A and Ap4A presented a clear reduction in IOP, with the others
presenting a hypertensive effect. Ap4A was a potent agonist and
produced a decrease in intraocular pressure (29.6% of decrease), at
concentrations 3 orders of magnitude below those at which Ap2A,
Ap3A, or Ap5A produced an increase. The dose-response curve for
Ap4A did not appear to inflect at the highest concentrations tested
points at which activation of the excitatory receptor might be
expected. At the lowest concentrations tested, none of Ap2A, Ap3A,
and Ap5A produced a decrease in intraocular pressure, which implies
that in addition to there being two separate populations of receptors,
one mediating an increase and the other a decrease in intraocular
pressure, this latter receptor is specific for Ap4A. It is possible that
Ap4A also activates the excitatory receptor, but in the mixed
FIGURE 3. Effect of nucleotides reducing IOP by acting on cholinergic
terminals located in the ciliary muscle. A. Under normal conditions the
irido-corneal angle (inside the circle) permits the drainage of the aqueous humour
through the trabeculum. B. P2X receptors present in cholinergic terminals from
the parasympathetic nervous system innervating the ciliary processes can stimulate
the release of more acetylcholine (ACh). This transmitter contracts the ciliary
muscle that pulls the scleral spur opening the irido-corneal angle therefore
reducing the hydrodynamic resistance of the aqueous humour.
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population the effects of activation of the receptor that mediates a
decrease in pressure predominated.
When investigating the place where Ap4A exert its action and in
clear contrast to what happen with mononucleotides, Ap4A facilitates
the drainage of the aqueous humour in the trabecular meshwork.
This fact leads us to hypothesize that, at least in part, the hypotensive
effect of Ap4A in eyes is mediated by an increase in aqueous outflow
(Figure 4). When instilled topically, dinucleotides are likely to
stimulate purinergic receptors present in the trabecular meshwork
to increase aqueous humour outflow as well as other purinergic
receptors present in the eye, such as those in the ciliary. Nevertheless,
the hypotensive effect of Ap4A seems to be well correlated with
the increase in outflow facility found here (44). By means of
immunocytochemical and western blot techniques we have described
the presence of P2Y1, P2Y2, and P2Y4 in bovine trabecular meshwork
cells. In contrast, the immunocytochemistry and Western blot results
seem to clearly indicate the absence of P2Y6 and P2Y11 purinoceptors.
Using the same antibodies, it was possible to identify these receptors
in rat ocular structures such as the corneal epithelium (P2Y6) and
the retinal pigmented epithelium (P2Y11) and to confirm the existence
of P2Y1 and P2Y2 in sections containing the trabecular meshwork
(44, 45). Other studies have also reported the presence of P2Y1 and
P2Y2 receptors in bovine trabecular meshwork cells (46) and P2Y1,
P2Y4, and P2Y11 in a human trabecular meshwork cell line (47).
ApnAs are known to activate several different purinergic receptors:
Ap3A and Ap4A both activate P2Y1 receptors with different selectivity,
whereas Ap5A is, in general, less effective at this receptor (48).
Furthermore, Ap4A is a good agonist at P2Y2 and P2Y4 receptors,
and although Ap3A and Ap5A can also activate these receptors,
they do so with less affinity. P2Y receptors act via a Gq/11 protein
coupling to activate PLC, IP3 formation, and mobilization of [Ca2 ]i,
although coupling to adenylyl cyclase, PLA2, PKC, NO synthase, or
BKCa channels activation has also been described (1).
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FIGURE 4. P2Y receptors present in trabecular meshwork cells. A. P2Y
receptors produce the shrink of trabecular meshwork cells this permitting the
facilitation of the aqueous humour drainage. B. Visualization of a single
trabecular meshwork cell in culture after being challenged with Ap4A. It can be
noticed how the cell shrinks after the superfusion of the dinucleotide.
CONCLUDING REMARKS
The function of mono and dinucleotides in the eye indicates that
these group of substances are developing interesting roles in three
important ocular processes: tear production, wound healing and
intraocular pressure. They are present in tears and in the aqueous
humour, therefore indicating they are naturally activating and/or
modulating these physiological processes. In addition, the topical
administration of some of these compounds can rescue the eye from
some pathological situations.
We are not so far away from finding any of these compounds
in the pharmacy. Diquafosol, also termed Up4U, has passed FDA
requirements to soon appear in the USA market as a treatment for
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dry eye condition. Other such as denufosol, aka dCp4U, is on clinical
trials. This dinucleotide is useful for the treatment of the retinal
detachment since it reabsorbs the liquid that is accumulated between
photoreceptors and the retinal pigmented epithelium. Following the
same philosophy it will not be strange to see in the near future
pharmaceutical compounds based on dinucleotides suitable for the
treatment of ocular pathologies such as glaucoma, corneal wound
healing or ocular surface infections.
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